NICE TAs

Published date: 27 June 2018 Next review: 2021

Published date: 28 October 2015 We reviewed the evidence in September 2018. We found nothing new that affects the recommendations in this guidance.

September 2016: The European Medicines Agency has reviewed idelalisib and the marketing authorisation has been updated.

For people taking idelalisib as a first therapy, the marketing authorisation now states that idelalisib is for ‘first-line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies’.

Additional information about infections has been included in the marketing authorisation.

Published date: 22 November 2017 Next review: More evidence on ibrutinib is being collected, until September 2020. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.

Published date: 25 January 2017 Next review: 2020

Published date: 31 January 2018 Next review: 2021

Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).

Published date: 11 October 2017 Next review: 2020

Published date: 22 July 2015 We reviewed the evidence in July 2018. We found nothing new that affects the recommendations in this guidance.

Published date: 27 March 2019 Next review: 2022

Published date: 22 August 2018 Next review: 2021 There is a simple discount patient access scheme for dinutuximab beta.

More evidence on daratumumab is being collected, until November 2020. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.

Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.

Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.

Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating diabetic macular oedema in adults.

Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

NICE is unable to recommend the use in the NHS of bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab or a rituximab-containing regimen because no evidence submission was received from the manufacturer or sponsor of the technology.

Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults.

Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative precursor B-cell acute lymphoblastic leukaemia in adults.

Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults.